Goleta, CA, United States of America

Jone Lin

This inventor holds 2 USPTO granted patents. Top assignee: Dako Denmark A/s. Active years: 2012-2013.


% Patents Active = 50.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2012-2013

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jone Lin: Innovator in Cancer Diagnostics

Introduction

Jone Lin is a notable inventor based in Goleta, California. He has made significant contributions to the field of cancer diagnostics, particularly through his work on Human Papilloma Virus (HPV) probes. With a total of 2 patents, Lin's innovations are paving the way for improved detection methods in oncology.

Latest Patents

One of Lin's latest patents focuses on the development of human papilloma virus probes for the diagnosis of cancer. This invention relates to a method of detecting cervical cancer and other types of cancer using a combination of at least three genomic clones or fragments of high-risk Human Papilloma Virus. The composition comprises at least three full-length genomic clones or fragments of high-risk Human Papilloma Viruses, enhancing the accuracy of cancer detection.

Career Highlights

Jone Lin is currently associated with Dako Denmark A/S, where he continues to innovate in the field of cancer diagnostics. His work has been instrumental in advancing methodologies that aid in the early detection of various cancers, thereby improving patient outcomes.

Collaborations

Lin collaborates with talented professionals in his field, including Kirsten Bisgaard-Franzen and Miu Fun Chau. These partnerships foster a collaborative environment that enhances the development of innovative solutions in cancer diagnostics.

Conclusion

Jone Lin's contributions to cancer diagnostics through his patents on HPV probes demonstrate his commitment to improving healthcare. His work not only reflects his expertise but also his dedication to advancing medical technology for better patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…